Pyrazolopyrimidines as crf receptor antagonists

This invention about has chemical type (I) of compounds contains optical heterogeneous property and medicine Shang can accept of acid plus into salt forms, which R1 for NR4R5 or OR5;R2 for C1-6 alkyl, and C1-6 n-oxygen base or C1-6 sulfur generation alkyl; R3 for hydrogen, and C1-6 alkyl, and C1-6 alkyl sulfonic acyl, and C1-6 alkyl Asia sulfonic acyl or C1-6 sulfur generation alkyl; R4 for hydrogen, and C1-6 alkyl, and single or II (C3-6 ring alkyl) methyl, and C3-6 ring alkyl, and C3-6 Ene base, and Hydroxyl C1-6 alkyl, and C1-6 alkyl Carbonyl oxygen C1-6 alkyl or C1-6 n-oxygen base C1-6 alkyl; R5 for C1-8 alkyl, and single or II (C3-6 ring alkyl) methyl, and Ar1CH2, and C1-6 n-oxygen base C1-6 alkyl, and hydroxyl C1-6 alkyl, and C3-6 Ene base, and h-Thiophene base methyl, and furan base methyl, and C1-6 alkyl sulfur generation C1-6 alkyl, and did imidacloprid base, and single or II (C1-6 alkyl) amine base C1-6 alkyl, and II (C1-6 alkyl) amine base, and C1-6 alkyl Carbonyl C1-6 alkyl, and to meters h base replaced of C1-6 alkyl; or chemical type-Alk-O-CO-Ar1 of group; or R4 and the R5 can with by connection of nitrogen Atomic together formed depending on needs replaced of h-slightly alkyl, and piperazine piperidine base, and Gao Paiding base or did imidacloprid base; has CRF receptor antagonist anti-agent nature; contains this species compounds as activity components of medicine composed property; through with effective volume of chemical type (I) of compounds treatment such as depression, and anxiety, and Diseases associated with excessive secretion of CRF, such as substance abuse.